Medical News

RSS

Study shows more women die of heart disease each year than men

Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.

10 Feb 2010

Model Metrics launches Pharma2GO sales force automation solution for pharma and life science industries

Model Metrics has launched Pharma2GO Spring '10, a comprehensive sales force automation solution specifically designed for the pharmaceutical and life science industries that extends the power of Salesforce CRM to mobile devices.

10 Feb 2010

Getinge Canada named 'Top 50 Best Small and Medium Employers in Canada' for 2009

Getinge Canada Limited is honoured to be named among the Top 50 Best Small and Medium Employers in Canada for 2009. This reflects positively on the employees and their engagement in the growth of this organization. The study, now in its sixth year, is published in the Globe and Mail and PROFIT Magazine.

10 Feb 2010

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Celsion Corporation announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.

10 Feb 2010

Majority of parents worry about safety of H1N1 vaccine

Ask any health professional who cares for children and they will tell you: When H1N1 flu hits, it can be very severe. In the last four months of 2009, nearly 240 children died in the United States from H1N1 flu—more than three times as many child deaths as in a typical non-H1N1 flu season.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

YM BioSciences receives additional AeroLEF patents in U.S.

YM BioSciences Inc., announced that it has been granted two additional patents in the US for AeroLEF(R), the Company's proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe acute pain. US patent numbers 7,648,981 and 7,648,982 extend the life of YM's AeroLEF patent estate in the US to 2024.

10 Feb 2010

Practice Fusion patient survey: Doctors are making use of EHR systems

The health IT landscape has changed fundamentally in the first year since the American Recovery and Reinvestment Act was signed into law. American patients are seeing their doctors make the switch to Electronic Health Record (EHR) systems, according to a survey conducted by GfK Roper for Practice Fusion, the fastest growing EHR community in the US.

10 Feb 2010

STDUniversity.org launches interactive, personalized STD test recommendation

STDUniversity.org is the first website to provide an interactive, personalized STD test recommendation developed by academic and medical experts. This expert-based tool incorporates screening guidelines from the Centers for Disease Control and Prevention (CDC), U.S. Agency for Healthcare Research and Quality (AHRQ), and the U.S. Preventive Service Task Force (USPSTF).

10 Feb 2010

New OKI Semiconductor module offers improved automated fingerprint identification and access control

The new OKI Semiconductor MK67Q5250 fingerprint matching module is designed to speed implementation of automated fingerprint identification and access control in applications ranging from locks and garage door openers to portable devices, computer workstations and POS terminals.

10 Feb 2010

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has signed agreements to divest its remaining MDS Pharma Services Early Stage business, which provides Discovery through Phase IIa clinical trial services to biotechnology and pharmaceutical companies, for $45 million and certain minority equity interests.

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Update on SOKO Fitness & Spa Group's recently broadened geographic expansion strategy

SOKO Fitness & Spa Group, Inc. ("SOKO" or the "Company"), an operator of fitness centers, beauty salons and spas in Northeast China as well as suburban Beijing, today provided an update on its recently broadened geographic expansion strategy.

10 Feb 2010

Goodwin Biotechnology, Macrocyclics announce collaboration on Chelation and Bioconjugation

Goodwin Biotechnology Inc., a full service Contract Biomanufacturing Company and Macrocyclics, Inc., a manufacturer of customized chelating agents, jointly announced today their collaborative agreement on Chelation and Bioconjugation. The collaboration will strengthen joint customer projects in Nuclear Medicine involving Chelation, Bioconjugation and GMP manufacturing.

10 Feb 2010

CMA launches Physician Assistant Toolkit

The Canadian Medical Association (CMA), in partnership with the Canadian Association of Physician Assistants (CAPA) today launched the "Physician Assistant Toolkit", designed to enhance awareness and answer physician questions surrounding the role of physician assistants (PAs).

10 Feb 2010

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Avrio Biopharmaceuticals, LLC, a wholly-owned subsidiary of Irvine Pharmaceutical Services, Inc., received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB), completing the organization's portfolio of product development services in support of its pharmaceutical, biopharmaceutical, and medical device clients.

10 Feb 2010

IndicatorEDG survey reveals Americans find less chance of achieving personal dreams

Luth Research's IndicatorEDG survey finds Americans are less likely to feel their dreams are attainable. Back in the third quarter of 2006, 62% of Americans said they had an excellent, very good or good chance of achieving their personal dreams.

10 Feb 2010

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

10 Feb 2010

UnitedHealth Group pays annual dividend to shareholders; renews Share Repurchase Program

UnitedHealth Group (NYSE:UNH) announced today that its Board of Directors, at its regular meeting on February 9, 2010, authorized payment of an annual dividend to shareholders for 2010.

10 Feb 2010

Medical News

Study shows more women die of heart disease each year than men

Model Metrics launches Pharma2GO sales force automation solution for pharma and life science industries

Getinge Canada named 'Top 50 Best Small and Medium Employers in Canada' for 2009

DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer

Majority of parents worry about safety of H1N1 vaccine

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

YM BioSciences receives additional AeroLEF patents in U.S.

Practice Fusion patient survey: Doctors are making use of EHR systems

STDUniversity.org launches interactive, personalized STD test recommendation

New OKI Semiconductor module offers improved automated fingerprint identification and access control

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Update on SOKO Fitness & Spa Group's recently broadened geographic expansion strategy

Goodwin Biotechnology, Macrocyclics announce collaboration on Chelation and Bioconjugation

CMA launches Physician Assistant Toolkit

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

IndicatorEDG survey reveals Americans find less chance of achieving personal dreams

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

UnitedHealth Group pays annual dividend to shareholders; renews Share Repurchase Program

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News